CRADD sirna

CRADD siRNA (Human)

Cat. Num. AAA8207362

• Gene Names: CRADD; MRT34; RAIDD
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: CRADD; CRADD siRNA (Human); RAIDD; Death domain-containing protein CRADD; Caspase and RIP adapter with death domain; RIP-associated protein with a death domain; CRADD sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: CRADD siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 103

• Applicable Applications for CRADD sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human CRADD gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for CRADD sirna

siRNA to inhibit CRADD expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 4503031
• NCBI GeneID: 8738
• NCBI Accession #: NP_003796.1
• NCBI GenBank Nucleotide #: NM_003805.3
• UniProt Accession #: P78560; B7Z2Q5
• Molecular Weight: 11,826 Da
• NCBI Official Full Name: death domain-containing protein CRADD
• NCBI Official Synonym Full Names: CASP2 and RIPK1 domain containing adaptor with death domain
• NCBI Official Symbol: CRADD
• NCBI Official Synonym Symbols: MRT34; RAIDD
• NCBI Protein Information: death domain-containing protein CRADD
• UniProt Protein Name: Death domain-containing protein CRADD
• Protein Family: Death domain-containing protein
• UniProt Gene Name: CRADD
• UniProt Synonym Gene Names: RAIDD
• UniProt Entry Name: CRADD_HUMAN

NCBI Description

The protein encoded by this gene is a death domain (CARD/DD)-containing protein and has been shown to induce cell apoptosis. Through its CARD domain, this protein interacts with, and thus recruits, caspase 2/ICH1 to the cell death signal transduction complex that includes tumor necrosis factor receptor 1 (TNFR1A), RIPK1/RIP kinase, and numbers of other CARD domain-containing proteins. [provided by RefSeq, Jul 2008]

Uniprot Description

CRADD: Apoptotic adaptor molecule specific for caspase-2 and FASL/TNF receptor-interacting protein RIP. In the presence of RIP and TRADD, CRADD recruits caspase-2 to the TNFR-1 signalling complex. Defects in CRADD are the cause of mental retardation autosomal recessive type 34 (MRT34). A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptative behavior and manifested during the developmental period. MRT34 is a non- syndromic form. Affected individuals have mildly delayed development and significantly impaired cognitive function, precluding independent living and self-care. Speech is rudimentary, but articulate; autism is not present.

Protein type: Apoptosis; Adaptor/scaffold

Chromosomal Location of Human Ortholog: 12q21.33-q23.1

Cellular Component: cytoplasm; nucleus

Molecular Function: protein binding, bridging; protein binding; protease binding

Biological Process: caspase activation; induction of apoptosis via death domain receptors; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest

Disease: Mental Retardation, Autosomal Recessive 34